Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Erenumab - a promising...

    Erenumab - a promising drug for chronic migraine associated with medication overuse

    Written by Medha Baranwal Baranwal Published On 2019-05-19T19:30:55+05:30  |  Updated On 19 May 2019 7:30 PM IST
    Erenumab - a promising drug for chronic migraine associated with medication overuse

    USA: A phase 2 trial showed Erenumab to be a promising drug for patients with chronic migraine (CM) and medication overuse. Erenumab is a fully human anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody approved for migraine prevention with demonstrated clinically relevant efficacy in CM.


    The study, published in the journal Neurology, found that in patients with chronic migraine and medication overuse, erenumab reduced acute migraine-specific medication treatment days and migraine frequency, improving quality of life and disability.


    Chronic migraine is defined as more than fifteen headache days per month over a three month period. It is difficult to treat and is often accompanied by excessive use of acute medications -- medication overuse (MO) in an attempt to manage their symptoms. Initiating a preventive treatment and cessation of acute treatments are two debatable options for treatment of patients with CM and MO.


    Stewart J. Tepper, Geisel School of Medicine at Dartmouth, Hanover, NH, and colleagues set to determine whether erenumab is beneficial in patients with chronic migraine and medication overuse.


    For the purpose, the researchers conducted a preplanned subgroup analysis of the double-blind, placebo-controlled phase 2 trial. 667 adults with CM were randomized (3:2:2) to placebo or erenumab (70 or 140 mg), stratified by region and medication overuse status.


    Data from patients with baseline medication overuse at baseline were used to assess changes in monthly migraine days, acute migraine-specific medication treatment days, and proportion of patients achieving ≥50% reduction from baseline in monthly migraine days.


    Also Read: Cognitive‐behavioral therapy reduces headache frequency in chronic migraine

    They found that:

    • Of the 667 patients randomized, 41% met criteria for MO.

    • Compared with the non-MO subgroup, the MO subgroup had a higher percentage with prior treatment failure with at least one preventive treatment (75% vs. 63%) and higher mean baseline monthly migraine days (19.0 days vs. 17.3 days).

    • At month 3, patients in the MO subgroup experienced reduced mean monthly migraine days with erenumab versus placebo (140 mg: −6.6 days; 70 mg: −6.6 days placebo: −3.5 days) and acute migraine-specific medication treatment days (140 mg: −4.9 days; 70 mg: −5.4 days; placebo: −2.1 days).

    • The observed treatment effects were similar in the non-MO subgroup.


    Also Read: Vagus Nerve Stimulation device approved by FDA for prevention of Chronic Migraine

    Previous studies, along with the current study of erenumab, support that, contrary to previous suggestions, headache preventive medications are not necessarily limited by acute headache medication overuse.


    "Overall, these results demonstrate that erenumab is effective in patients with CM and medication overuse with clinical improvements in reduction of the frequency of migraines and with improvements in patient-reported outcomes (PROs) across multiple measures of health-related quality of life (HRQOL), social and psychological impact, and disability in patients with CM," concluded the authors.


    For detailed study follow the link: https://doi.org/10.1212/WNL.0000000000007497

    calcitonin gene-related peptideCGRPchronicdisabilityErenumabHeadachehuman monoclonal antibodymedicationmedication overusemonoclonal antibodyNeurology journalQuality of lifeStewart J. Teppertreatmenttreatment days
    Source : With inputs from Neurology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok